Sanofi, Regeneron burnish their blockbuster Dupixent franchise with positive results in children with uncontrolled eczema
As a stable of new players sets out to topple Dupixent’s status as the reigning antibody treatment for atopic dermatitis, the blockbuster’s developers are moving the goalposts.
Dupixent has aced a Phase III trial involving 162 children between 6 months and 5 years old, Sanofi and Regeneron say, becoming the first biologic drug to show efficacy in this young population. When given Dupixent on top of standard of care topical corticosteroids, 28% of patients achieved clear or almost-clear skin compared to 4% of those on placebo — thus meeting the primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
